Biofrontera – planning the next phase
The first of February marked a milestone for Leverkusen-based Biofrontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date that Biofrontera began to execute a licencing strategy for the rest of Europe for the treatment of actinic keratosis. Biofrontera is planning to target Scandinavian markets together with distribution partner Desitin Arzneimittel GmbH next. The Hamburg-based company has specialised in drug distribution in Germany, Scandinavia and Eastern Europe. Biofrontera is receiving an undisclosed down-payment to supply Desitin with the product and help support pharmacovigilance studies.